Eli Lilly’s drug cuts COVID-19 recovery time in remdesivir-combo study – Reuters India
Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc’s remdesivir.
